Bollard Group’s Vera Therapeutics VERA Stock Holding History

Bollard Group’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-64,042	Closed	-$1.51M	–	296
2025 Q2	$1.51M	Buy	+64,042	New	+$1.44M	0.03%	103

Other funds holding VERA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bollard Group's VERA Position: Q3 2025 in Review

Bollard Group sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 64,042 shares — an estimated $1.51M sold.

Bollard Group first reported a position in VERA in Q2 2025 and held it in 1 quarter. The position peaked at $1.51M in Q2 2025. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

Bollard Group reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
Bollard Group sold 64,042 Vera Therapeutics shares in Q3 2025, an estimated $1.51M.
Bollard Group first reported a position in Vera Therapeutics in Q2 2025 and held it in 1 quarter.
Bollard Group's Vera Therapeutics position peaked at $1.51M in Q2 2025.
175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Bollard Group's 13F filing for Q3 2025, filed 14 Nov 2025.